Treatment of Plasmodium vivax Malaria in Non-Pregnant Adults with Normal G6PD Activity
For a non-pregnant adult with uncomplicated P. vivax malaria and confirmed normal G6PD activity, treat with chloroquine (25 mg/kg total dose over 3 days) followed by primaquine 15 mg daily for 14 days to achieve radical cure and prevent relapse.
Blood Stage Treatment
The blood schizontocidal component should be chloroquine administered as 1:
- 600 mg at 0 hours
- 600 mg at 24 hours
- 300 mg at 48 hours
- Total dose: 1,500 mg (approximately 25 mg/kg body weight)
This regimen remains effective for chloroquine-sensitive P. vivax, which includes most geographic regions outside of Papua New Guinea, Indonesia, and parts of Southeast Asia 2.
Radical Cure to Prevent Relapse
Critical consideration: P. vivax forms dormant liver stages (hypnozoites) that cause relapse if not eradicated. Without radical cure, relapse rates reach 9.3% for P. vivax 2.
Standard Primaquine Regimen
For patients with confirmed normal G6PD activity, administer primaquine 15 mg daily for 14 days 1. This achieves the recommended total dose of 3.5 mg/kg and provides an 80% risk reduction in relapse 2.
Alternative Regimens
Higher-dose shorter course: A 7-day primaquine regimen (0.5 mg/kg/day, total 3.5 mg/kg) is now WHO-endorsed and shows comparable efficacy with improved adherence 2, 3. Recent data from Nepal demonstrated no recurrences at 6 months with this regimen 3.
Single-dose tafenoquine: For adults ≥16 years with G6PD activity >70%, tafenoquine 300 mg as a single dose is highly effective. Brazilian real-world data showed 88.6% recurrence-free effectiveness at day 90, superior to 7-day primaquine (83.5%) in the first 90 days 4. However, tafenoquine requires quantitative G6PD testing (not just qualitative screening) and is only approved when co-administered with chloroquine 2, 5.
Critical Safety Considerations
G6PD Testing is Mandatory
Never administer primaquine or tafenoquine without G6PD testing 1, 2. The 1992 guidelines explicitly warn that primaquine administration beyond 5 days in G6PD-deficient patients "may result in life-threatening hemolysis" 1.
- Quantitative testing preferred: Particularly important in females who may have intermediate G6PD activity (30-70%) due to X-linked inheritance 2, 6
- Point-of-care quantitative G6PD testing enables same-day treatment decisions 4
For G6PD Deficiency or Intermediate Activity
If G6PD activity is <70% but ≥30%, use primaquine 0.75 mg/kg weekly for 8 weeks 2, 4. This weekly regimen is safer in G6PD deficiency while still providing radical cure.
Geographic Considerations for Chloroquine Resistance
In areas with documented chloroquine resistance (Papua New Guinea, Indonesia, Sabah where failure exceeds 10%), use artemisinin-based combination therapy (ACT) instead 2:
- Dihydroartemisinin-piperaquine shows superior efficacy (HR 2.33 over chloroquine at day 42-63) 2
- Artemether-lumefantrine is also effective 2
Follow ACT with the same primaquine radical cure regimen.
Monitoring and Follow-Up
- Repeat thick smear if symptomatic beyond 3 days: Alternative therapy indicated if parasitemia hasn't markedly diminished 1
- Monitor for relapse: Median time to recurrence is 68-92 days, so clinical vigilance for 6 months is warranted 4
- Hemoglobin monitoring: Check baseline and Day 2-7 hemoglobin, particularly watching for ≥25% drops, though severe hemolysis is rare with normal G6PD 3
Common Pitfalls to Avoid
- Omitting radical cure: Treating only the blood stage leaves hypnozoites intact, virtually guaranteeing relapse
- Skipping G6PD testing: This is the most dangerous error—can cause life-threatening hemolysis
- Using qualitative G6PD tests in females: May miss intermediate deficiency; quantitative testing is essential 2, 6
- Assuming all P. vivax is chloroquine-sensitive: Know the geographic origin of infection 2
- Poor adherence to 14-day primaquine: Consider directly observed therapy or shorter regimens when adherence is questionable 3, 4